Table 1 Patient characteristics per side and lobe among patients diagnosed with lung cancer in 2018–2022 in Norway
From: Distribution and characteristics of malignant tumours by lung lobe
Lobe | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RUL | LUL | RML | RLL | LLL | Total | |||||||
All | 3,381 | (31.2%) | 2,796 | (25.8%) | 587 | (5.4%) | 2,328 | (21.5%) | 1,757 | (16.2%) | 10,849 | (100.0%) |
Age | 70.2 | (8.9) | 70.8 | (8.9) | 69.7 | (10.2) | 70.6 | (9.6) | 71.0 | (9.3) | 70.5 | (9.2) |
Sex | ||||||||||||
Female | 1,564 | (46.3%) | 1,325 | (47.4%) | 329 | (56.0%) | 1,187 | (51.0%) | 884 | (50.3%) | 5,289 | (48.8%) |
Male | 1,817 | (53.7%) | 1,471 | (52.6%) | 258 | (44.0%) | 1,141 | (49.0%) | 873 | (49.7%) | 5,560 | (51.2%) |
Histology | ||||||||||||
AC | 1,796 | (53.1%) | 1,397 | (50.0%) | 287 | (48.9%) | 1,199 | (51.5%) | 899 | (51.2%) | 5,578 | (51.4%) |
SCC | 752 | (22.2%) | 668 | (23.9%) | 99 | (16.9%) | 577 | (24.8%) | 427 | (24.3%) | 2,523 | (23.3%) |
NSCLC, NOS | 270 | (8.0%) | 201 | (7.2%) | 27 | (4.6%) | 148 | (6.4%) | 95 | (5.4%) | 741 | (6.8%) |
Large-cell | 45 | (1.3%) | 33 | (1.2%) | 8 | (1.4%) | 30 | (1.3%) | 20 | (1.1%) | 136 | (1.3%) |
SCLC | 411 | (12.2%) | 398 | (14.2%) | 91 | (15.5%) | 270 | (11.6%) | 218 | (12.4%) | 1,388 | (12.8%) |
Carcinoid | 44 | (1.3%) | 36 | (1.3%) | 62 | (10.6%) | 61 | (2.6%) | 65 | (3.7%) | 268 | (2.5%) |
Other | 63 | (1.9%) | 63 | (2.3%) | 13 | (2.2%) | 43 | (1.8%) | 33 | (1.9%) | 215 | (2.0%) |
cTNM | ||||||||||||
I | 959 | (28.4%) | 768 | (27.5%) | 213 | (36.3%) | 716 | (30.8%) | 551 | (31.4%) | 3,207 | (29.6%) |
II | 283 | (8.4%) | 233 | (8.3%) | 39 | (6.6%) | 222 | (9.5%) | 195 | (11.1%) | 972 | (9.0%) |
III | 708 | (20.9%) | 539 | (19.3%) | 91 | (15.5%) | 434 | (18.6%) | 309 | (17.6%) | 2,081 | (19.2%) |
IV | 1,431 | (42.3%) | 1,256 | (44.9%) | 244 | (41.6%) | 956 | (41.1%) | 702 | (40.0%) | 4,589 | (42.3%) |
MDT | ||||||||||||
No | 797 | (23.6%) | 664 | (23.7%) | 125 | (21.3%) | 554 | (23.8%) | 417 | (23.7%) | 2,557 | (23.6%) |
Yes | 2,584 | (76.4%) | 2,132 | (76.3%) | 462 | (78.7%) | 1,774 | (76.2%) | 1,340 | (76.3%) | 8,292 | (76.4%) |
PET-CT | ||||||||||||
No | 1,174 | (34.7%) | 991 | (35.4%) | 204 | (34.8%) | 789 | (33.9%) | 585 | (33.3%) | 3,743 | (34.5%) |
Yes | 2,207 | (65.3%) | 1,805 | (64.6%) | 383 | (65.2%) | 1,539 | (66.1%) | 1,172 | (66.7%) | 7,106 | (65.5%) |
EBUS | ||||||||||||
No | 2,419 | (71.5%) | 2,192 | (78.4%) | 430 | (73.3%) | 1,711 | (73.5%) | 1,342 | (76.4%) | 8,094 | (74.6%) |
Yes | 962 | (28.5%) | 604 | (21.6%) | 157 | (26.7%) | 617 | (26.5%) | 415 | (23.6%) | 2,755 | (25.4%) |
EGFR-test | ||||||||||||
Not tested | 1,432 | (42.4%) | 1,316 | (47.1%) | 294 | (50.1%) | 1,068 | (45.9%) | 809 | (46.0%) | 4,919 | (45.3%) |
Positive | 199 | (5.9%) | 170 | (6.1%) | 31 | (5.3%) | 111 | (4.8%) | 91 | (5.2%) | 602 | (5.5%) |
Negative | 1,692 | (50.0%) | 1,255 | (44.9%) | 255 | (43.4%) | 1,118 | (48.0%) | 825 | (47.0%) | 5,145 | (47.4%) |
Unknown | 58 | (3.0%) | 55 | (3.7%) | 7 | (2.4%) | 31 | (2.5%) | 32 | (3.4%) | 183 | (3.1%) |
First treatment | ||||||||||||
Resected | 871 | (25.8%) | 721 | (25.8%) | 196 | (33.4%) | 693 | (29.8%) | 532 | (30.3%) | 3,013 | (27.8%) |
SBRT | 294 | (8.7%) | 211 | (7.5%) | 30 | (5.1%) | 197 | (8.5%) | 145 | (8.3%) | 877 | (8.1%) |
Curative RT | 435 | (12.9%) | 337 | (12.1%) | 56 | (9.5%) | 227 | (9.8%) | 177 | (10.1%) | 1,232 | (11.4%) |
Palliative RT | 703 | (20.8%) | 585 | (20.9%) | 90 | (15.3%) | 430 | (18.5%) | 313 | (17.8%) | 2,121 | (19.6%) |
Unknown RT | 22 | (0.7%) | 19 | (0.7%) | 2 | (0.3%) | 9 | (0.4%) | 16 | (0.9%) | 68 | (0.6%) |
No treatment reported | 1,056 | (31.2%) | 923 | (33.0%) | 213 | (36.3%) | 772 | (33.2%) | 574 | (32.7%) | 3,538 | (32.6%) |